金雀花碱与伐尼克兰对戒烟效果的影响:一项随机临床试验
该非劣效、开放标签随机临床试验在澳大利亚纳入1452名愿意戒烟的成年每日吸烟者,比较25天金雀花碱方案(n=725)与84天伐尼克兰方案(n=727),所有参与者均被提供电话行为支持转介。主要终点为7个月随访时经一氧化碳呼气试验验证的6个月持续戒断率。
要点
- 在1452名澳大利亚成年每日吸烟者中,25天金雀花碱方案对比84天伐尼克兰方案未能证明戒烟非劣效(风险差-1.62%,单侧97.5%CI -5.02%至∞)。
- 验证的6个月持续戒断率:金雀花碱组11.7%,伐尼克兰组13.3%。
- 金雀花碱组自我报告不良事件较少(482名参与者共997起事件 vs 510名参与者共1206起事件;发生率比0.88,95%CI 0.81-0.95)。
- 金雀花碱给药方案:1.5 mg胶囊,初始每日6次,25天疗程内逐渐减量;伐尼克兰:0.5 mg片剂滴定至1 mg每日两次,84天(12周)。
- 所有参与者均被提供转介至标准电话行为支持。
适用人群与场景
- 澳大利亚成年每日吸烟者,愿意尝试戒烟;共1452名随机分组(平均[SD]年龄42.9[12.7]岁;742名[51.1%]女性)。
- 研究在澳大利亚进行,2017年11月至2019年5月,随访于2020年1月完成;数据收集主要通过计算机辅助电话访谈,但主要终点有一次面对面访视验证。
诊断标准与关键阈值
- 主要终点:7个月随访时经一氧化碳呼气试验验证的6个月持续戒断。
处置流程与药物剂量
- 金雀花碱组(n=725):按制造商推荐剂量,1.5 mg胶囊,初始每日6次,然后在25天疗程内逐渐减量。
- 伐尼克兰组(n=727):按制造商推荐剂量,0.5 mg片剂滴定至1 mg每日两次,持续84天(12周)。
- 所有参与者均被提供转介至标准电话行为支持。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究设计:非劣效、开放标签随机临床试验,采用分配隐藏和盲法结局评估;共1452名参与者,在澳大利亚进行;1108名(76.3%)完成试验。
证据类型、等级与局限
- 证据类型:非劣效、开放标签随机临床试验,分配隐藏,盲法结局评估。
- 局限:开放标签设计;主要依赖计算机辅助电话访谈收集数据;非劣效性未达到;原文未提及证据等级或推荐强度。
对床旁实践的改变
- 对于愿意戒烟的每日吸烟者,25天金雀花碱方案不能替代84天伐尼克兰方案作为非劣效选择;伐尼克兰仍是更有效的戒烟药物选择。
- 金雀花碱组不良事件发生率较低,但戒烟效果未达非劣效,临床决策需权衡疗效与耐受性。
- 所有参与者均接受电话行为支持转介,提示药物治疗应结合行为支持。
指南或共识出处
- 原文未提及指南或共识;试验注册:anzctr.org.au Identifier: ACTRN12616001654448。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Cytisine is more effective than placebo and nicotine replacement therapy for smoking cessation. However, cytisine has not been tested against the most effective smoking cessation medication, varenicline, which is associated with adverse events known to lead to discontinuation of therapy.
OBJECTIVE: To examine whether standard cytisine treatment (25 days) was at least as effective as standard varenicline treatment (84 days) for smoking cessation.
DESIGN, SETTING, AND PARTICIPANTS: This noninferiority, open-label randomized clinical trial with allocation concealment and blinded outcome assessment was undertaken in Australia from November 2017 through May 2019; follow-up was completed in January 2020. A total of 1452 Australian adult daily smokers willing to make a quit attempt were included. Data collection was conducted primarily by computer-assisted telephone interview, but there was an in-person visit to validate the primary outcome.
INTERVENTIONS: Treatments were provided in accordance with the manufacturers' recommended dosage: cytisine (n = 725), 1.5-mg capsules taken 6 times daily initially then gradually reduced over the 25-day course; varenicline (n = 727), 0.5-mg tablets titrated to 1 mg twice daily for 84 days (12 weeks). All participants were offered referral to standard telephone behavioral support.
MAIN OUTCOMES AND MEASURES: The primary outcome was 6-month continuous abstinence verified using a carbon monoxide breath test at 7-month follow-up. The noninferiority margin was set at 5% and the 1-sided significance threshold was set at .025.
RESULTS: Among 1452 participants who were randomized (mean [SD] age, 42.9 [12.7] years; 742 [51.1%] women), 1108 (76.3%) completed the trial. Verified 6-month continuous abstinence rates were 11.7% for the cytisine group and 13.3% for the varenicline group (risk difference, -1.62% [1-sided 97.5% CI, -5.02% to ∞]; P = .03 for noninferiority). Self-reported adverse events occurred less frequently in the cytisine group (997 events among 482 participants) compared with the varenicline group (1206 events among 510 participants) and the incident rate ratio was 0.88 (95% CI, 0.81 to 0.95; P = .002).
CONCLUSIONS AND RELEVANCE: Among daily smokers willing to quit, cytisine treatment for 25 days, compared with varenicline treatment for 84 days, failed to demonstrate noninferiority regarding smoking cessation.
TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12616001654448.
参考来源
- Courtney RJ, McRobbie H, Tutka P, et al. Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial. JAMA. 2021. PMID: 34228066. doi:10.1001/jama.2021.7621
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。